< Back to previous page
Laboratory of Protein Phosphorylation and Proteomics
Main organisation:Department of Cellular and Molecular Medicine
Lifecycle:1 Oct 2007 → Today
- We investigate the regulation of (patho)physiological processes via reversible protein phosphorylation, and explore the therapeutic potential of the kinases and phosphatases involved. Focus is on Protein Kinase D (PKD) and Protein Phosphatase 2A (PP2A), but increasingly also on broader (kinome and phosphatome wide) approaches to systematically identify kinases/phosphatases that are implicated in (patho)physiological processes.
- We study the molecular regulation of PKD2 and its role in various cancer hallmarks. In addition, we are developing PKD inhibitors, including some that exploit novel (allosteric) inhibitory mechanisms.
- For PP2A, the focus is mainly on its tumor suppressive abilities and its deregulation in cancer, but we also study its role in neurodegenerative and cardiovascular diseases, and in basic cell biological process (mitosis, cell migration).
- We apply (and further develop) mass spectrometric approaches for (phospho)proteomic and lipidomic and molecular imaging (imaging mass spectrometry) analysis to solve biomedical questions.
Keywords:neurodegeneration, kinase inhibitor, protein phosphatases, protein kinases, cancer, lipidomics, proteomics, mass spectrometry, cardiovascular, allosteric inhibitor, allostery, phosphatome, kinome
Disciplines:Morphological sciences, Oncology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Biochemistry and metabolism, Medical biochemistry and metabolism, Systems biology